Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate

SIMPLE SUMMARY: Since the approval of durvalumab for the treatment of unresectable non-small-cell lung cancer UICC stage III, the 5-year overall survival rates have risen from below 20% to 50%. Although the validity of lung function testing has been questioned, for long-term survivors, residual pulm...

Descripción completa

Detalles Bibliográficos
Autores principales: Stana, Markus, Grambozov, Brane, Karner, Josef, Gollner, Isabella, Gaisberger, Christoph, Ruznic, Elvis, Zellinger, Barbara, Moosbrugger, Raphaela, Studnicka, Michael, Fastner, Gerd, Sedlmayer, Felix, Zehentmayr, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092995/
https://www.ncbi.nlm.nih.gov/pubmed/37046627
http://dx.doi.org/10.3390/cancers15071966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092995/
https://www.ncbi.nlm.nih.gov/pubmed/37046627
http://dx.doi.org/10.3390/cancers15071966

Ejemplares similares